Reports Q4 revenue $290.4M, consensus $277.2M. “2025 was a defining year for Tandem as we surpassed $1 billion in worldwide sales and set gross margin records, while modernizing our commercial operations, reshaping our business model, and driving innovation,” said John Sheridan, president and chief executive officer. “In 2026, we plan to build upon this momentum as we further strengthen our business, while delivering new technology solutions to improve the lives of people with diabetes.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- TNDM Upcoming Earnings Report: What to Expect?
- Tandem Diabetes price target raised to $20 from $16 at Stifel
- Tandem Diabetes coverage transferred with a Buy at TD Cowen
- Tandem Diabetes Care: Multi‑Phase Growth Reacceleration Driven by Patch Pump Launch and Margin Recovery Supports Upgraded $25 Target
- Tandem Diabetes price target raised to $25 from $18 at Bernstein